Amarin Corp Plc (AMRN)

[rfj1862]

https://www.biorxiv.org/content/early/2018/11/09/466649

BOOM $9BN potential per year alone in the USA assuming no price rises.

I am starting to believe JL and other super bullish price targets when I see articles like this....

This is a big deal. A peer-reviewed, reasonably well conducted evaluation demonstrating that the market for Vascepa is actually in the $9 billion range.

Of course that's assuming that the entry criteria from REDUCE-IT are strictly applied in order to qualify for the drug. I suspect there are at least a few billion more in sales for patients who don't fit the REDUCE-IT criteria precisely but are still at risk.

So...an $11 billion market minimum.